Matthew Lang J.D.
Net Worth

Last updated:

What is Matthew Lang J.D. net worth?

The estimated net worth of Mr. Matthew Lang J.D. is at least $7,893,760 as of 18 Jan 2023. He has earned $1,713,760 from insider trading and has received compensation worth at least $6,180,000 in Myovant Sciences Ltd..

What is the salary of Matthew Lang J.D.?

Mr. Matthew Lang J.D. salary is $1,030,000 per year as Gen. Counsel & Corporation Sec. in Myovant Sciences Ltd..

How old is Matthew Lang J.D.?

Mr. Matthew Lang J.D. is 49 years old, born in 1976.

What stocks does Matthew Lang J.D. currently own?

As insider, Mr. Matthew Lang J.D. owns shares in one company:

Company Title Shares Price per share Total value
Myovant Sciences Ltd. (MYOV) Gen. Counsel & Corporation Sec. 354,303 $0 $0

What does Myovant Sciences Ltd. do?

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

MYOV logo
MYOV
Myovant Sciences Ltd.

Matthew Lang J.D. insider trading

Myovant Sciences Ltd.

Mr. Matthew Lang J.D. has made 22 insider trades between 2019-2023, according to the Form 4 filled with the SEC. Most recently he sold 1,272 units of MYOV stock worth $34,204 on 18 Jan 2023.

The largest trade he's ever made was exercising 31,214 units of MYOV stock on 15 Aug 2022. As of 18 Jan 2023 he still owns at least 354,303 units of MYOV stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Shares 1,272 $26.89 $34,204
Sale
Common Shares 2,779 $26.9 $74,755
Sale
Common Shares 1,933 $25.2 $48,712
Sale
Common Shares 3,679 $24.4 $89,768
Sale
Common Shares 31,214 $18.23 $569,031
Sale
Common Shares 1,935 $12.87 $24,903
Sale
Common Shares 3,702 $13.4 $49,607
Sale
Common Shares 8,002 $10.45 $83,621
Sale
Common Shares 2,436 $13.78 $33,568
Sale
Common Shares 4,475 $16.27 $72,808
Sale
Common Shares 6,671 $21.62 $144,227
Sale
Common Shares 6,954 $21.52 $149,650
Sale
Common Shares 10,862 N/A N/A
Option
Stock Option (Right to Buy) 30,000 N/A N/A
Sale
Common Shares 30,000 N/A N/A
Option
Common Shares 30,000 $7.78 $233,400
Sale
Common Shares 10,000 $13.12 $131,180
Option
Common Shares 10,000 $7.78 $77,800
Option
Stock Option (Right to Buy) 10,000 $7.78 $77,800
Sale
Common Shares 19,400 N/A N/A
Option
Stock Option (Right to Buy) 19,400 N/A N/A
Option
Common Shares 19,400 $25.2 $488,783
Sale
Common Shares 600 N/A N/A
Option
Common Shares 600 $7.78 $4,668
Option
Stock Option (Right to Buy) 600 N/A N/A
Sale
Common Shares 26,700 $7.78 $207,726
Option
Common Shares 26,700 $7.78 $207,726
Option
Stock Option (Right to Buy) 26,700 N/A N/A
Option
Stock Option (Right to Buy) 2,600 N/A N/A
Sale
Common Shares 2,600 N/A N/A
Option
Common Shares 2,600 N/A N/A
Sale
Common Shares 100 N/A N/A
Option
Stock Option (Right to Buy) 100 N/A N/A
Option
Common Shares 100 N/A N/A
Sale
Common Shares 600 N/A N/A
Option
Stock Option (Right to Buy) 600 N/A N/A
Option
Common Shares 600 N/A N/A
Sale
Common Stock 19,018 N/A N/A

Myovant Sciences Ltd. key executives

Myovant Sciences Ltd. executives and other stock owners filed with the SEC: